Severity, Risk Factors and Quality of Life of Patients associated with Chemotherapy-Induced Peripheral Neuropathy

Clin Nurs Res. 2022 Jul;31(6):1080-1090. doi: 10.1177/10547738221085613. Epub 2022 Apr 1.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) refers to numbness, tingling, and burning sensation caused by chemotherapy that can cause impairment in Quality of Life (QoL) of the patients. Study assesses severity, risk factors, and quality of life of patients associated with CIPN. A cross sectional descriptive study was conducted at day care ward, tertiary care hospital India. Total of 98 patients receiving paclitaxel for ≥4 months were enrolled by convenient sampling. Data regarding demographics and clinical characteristics, CIPN severity, risk factors, and QoL were collected by structured questionnaires. Study revealed that median score of autonomic symptoms was higher than sensory and motor symptoms. Mean score of FACT/GOG-Ntx sub-domain was 99.05 ± 20.87on a scale of 0 to 152. ECOG Performance status, current exercise behavior, and fruit and vegetable intake was found to be significantly (at p < .05) associated with sensory, motor, and autonomic symptom score. Therefore, CIPN was found to have debilitating effect on QoL.

Keywords: chemotherapy induced peripheral neuropathy; clinical research areas; paclitaxel; quality of life; risk factors; severity.

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Cross-Sectional Studies
  • Humans
  • Peripheral Nervous System Diseases* / chemically induced
  • Peripheral Nervous System Diseases* / diagnosis
  • Peripheral Nervous System Diseases* / drug therapy
  • Quality of Life
  • Risk Factors

Substances

  • Antineoplastic Agents